Abstract
High-precision radiotherapy (HPR) of recurrent high grade glioma (HGG) requires accurate spatial allocation of these infiltrative tumors. We investigated the impact of 18F-FET PET on tumor delineation and progression of recurrent HGG after HPR with carbon ions. T1 contrast enhanced MRI and 18F-FET-PET scans of 26 HGG patients were fused with radiotherapy planning volumes. PET-positive (PET+) tumor volumes using different isocontours (I%) were systematically investigated and compared with MRI-derived gross tumor volumes (GTV). Standardized uptake ratios (SUR) were further correlated with GTV and tumor progression patterns. In grade IV glioma, SUR > 2.92 significantly correlated with poor median overall survival (6.5 vs 13.1 months, p = 0.00016). We found no reliable SUR cut-off criteria for definition of PET+ volumes. Overall conformity between PET and MRI-based contours was low, with maximum conformities between 0.42–0.51 at I40%. The maximum sensitivity and specificity for PET+ volumes outside of GTV predicting tumor progression were 0.16 (I40%) and 0.52 (I50%), respectively. In 75% of cases, FLAIR hyperintense area covered over 80% of PET+ volumes. 18F-FET-PET derived SUR has a prognostic impact in grade IV glioma. The value of substantial mismatches between MRI-based GTV and PET+ volumes to improve tumor delineation in radiotherapy awaits further validation in randomized prospective trials.
Similar content being viewed by others
Explore related subjects
Find the latest articles, discoveries, and news in related topics.Introduction
The prognosis of patients diagnosed with HGG remains poor, with median overall survival times of 10–15 months in grade IV glioma (glioblastoma multiforme, GBM) and 40–50 months in grade III glioma1. Local therapy failure poses a major obstacle in curative treatment of these patients2,3. High precision radiotherapy (HPR) holds the promise to escalate the dose in the tumor and improve local control while sparing normal tissue. Several ongoing trials are currently investigating the impact of HPR in treatment of recurrent high grade glioma (HGG)4,5. However, target delineation in HGG is challenging due to their infiltrative nature and heterogeneous tumor structure6. Current standard definition of the gross tumor volume (GTV) is primarily based on T1 weighted contrast-enhanced (T1 CE) magnetic resonance imaging (MRI)7. Potential extensions of the tumor and suspected microscopic infiltrations of the surrounding tissue are covered with an additional safety margin around the GTV, leading to the clinical target volume (CTV). More recent guidelines suggest the inclusion of volumes that are hyperintense on T2 fluid-attenuated inversion-recovery (FLAIR) MRI images, hence correlating with tumor-induced edema, into CTV7. However, to avoid toxicities such as radionecrosis in pre-irradiated normal tissue this region has to be maximally spared from high-dose volume in treatment of recurrent HGG. Therefore, the benefit of an improved local control via dose escalation with HPR could be compromised by narrow margins and inaccuracies in tumor delineation emphasizing the need for novel imaging modalities for precision medicine.
Biological imaging, e.g. assessment of tumor metabolism by amino-acid positron emission tomography (PET), may present a promising modality to assist in radiotherapy planning8,9. For tumor volume definition in recurrent HGG, L-[methyl-11C]methionine (11C-MET) PET and O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) were studied among others10,11,12,13. 18F-FET PET is increasingly used in clinical routine13,14,15,16,17,18,19. However, selection of appropriate segmentation technique for identification of the PET active volumes is still controversially debated. So far, a consensus strategy for PET based tumor delineation is not established20. Manual segmentation of the PET active area is subject to inter- and intra-rater variations, based on the applied level window and experience of the contouring physician. Semi-automatic techniques, like region growing or thresholding, depend on the definition of seed points and threshold values that vary between users and institutions. A method often utilized in cases of 18F-FDG PET is the application of a fixed threshold on the standardized uptake value (SUV)12. Yet, uptake of 18F-FET in malignant tissue is much lower compared to 18F-FDG, and varies greatly between patients21. Using percentage thresholds on the maximum SUV, so-called isocontours, can normalize inter-patient differences in uptake to an extent, but the optimal threshold value to be used is unclear and literature values vary between 40% and 90%14.
A popular new approach is the normalization of maximum SUV values (SUVmax) to the background signal of healthy brain, and applying a threshold on this ratio, but again the threshold values differ between authors11,19,22. Despite different methodological approaches employed most studies reported substantial mismatches between MRI based standard radiotherapy (RT) target definitions and 18F-FET active volumes. However, the extent of these mismatches has not been well studied and there is no consensus on a segmentation strategy that provides the optimum conformity or additional value of 18F-FET PET in RT target delineation. The presented study aims to quantify the mismatches and overlaps between T1 CE MRI and 18F-FET PET depending on the PET contouring technique. Furthermore, it was investigated whether the mismatches between the two modalities can be explained by tumor volumes not visible in the treatment planning MRI (i.e. areas of tumor recurrence) and should thus be included in the target volume.
Methods
All procedures performed in this were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional ethics committee (ethics committee of the University of Heidelberg, S-421/2015).
Patients, treatment planning and MRI
Imaging and radiotherapy treatment planning data from 26 patients with recurrent high-grade glioma was investigated in this IRB approved retrospective study. For this retrospective trial no informed consent was required. Patient characteristics are listed in Table 1. Out of the 26 patients, 12 were diagnosed with recurrent grade III glioma (3 secondary malignancies from astrocytoma grade II) and 14 with recurrent grade IV (GBM), including one secondary malignancy from a grade II astrocytoma.
Patients received 18F-FET PET scans and contrast enhanced MRI prior to radiotherapy, with no more than three weeks in between. All patients were treated at Heidelberg Ion-beam Therapy center (HIT) with carbon ions. Target structures GTV and CTV were delineated by the treating physician based on the T1 CE MRI and treatment planning CT. GTV included the contrast enhancing structures on T1 MR images and, if applicable, resection cavities from previous treatments. Tumors were irradiated with varying fraction schemes (10 to 14 fractions, median 11 fractions, of 3 GyE each (Gray Equivalent according to the local effect model, LEM 1))23.
18F-FET PET scans
18F-FET PET scans were acquired using a Siemens Biograph 6 PET/CT scanner. Median injected activity was 190 MBq, ranging from 130 to 235 MBq. In 16 patients, a dynamic acquisition over 40 min was performed, and endpoint static 18F-FET PET images were calculated by averaging the scans of the last 10 minutes. The endpoint static images featured a resolution of 1.33 mm × 1.33 mm × 3 mm, acquired over 80 slices. In 10 patients, only one-point static scans 30 min post-injection were conducted (resolution: 1.33 mm × 1.33 mm × 3 mm taken over 54 slices).
Magnetic Resonance Imaging
Images were acquired in the routine clinical workup using a 3 Tesla MR system (Magnetom Verio/Trio TIM, Siemens Healthcare, Erlangen, Germany) with a 12-channel head matrix coil. Briefly, the protocol included an isotropic T1-weighted 3D MPRAGE images (isotropic voxel size: 1 mm³) both before and after administration of a 0.1 mmol/kg dose of gadoterate meglumine (DOTAREM, Guerbet, France) as well as axial FLAIR and axial T2-weighted images (slice thickness 5 mm).
Image analysis and statistics
Image processing was done using the Medical Imaging Interaction ToolKit MITK (www.mitk.org)24. MITK is an open-source software framework for medical image procession and image analysis. Its toolkit nature allows for expansion with own implementations. MITK offers all analysis tools necessary for the envisioned analysis, including registration, integration of radiotherapy structure sets, segmentation and statistical volume assessment, in combination with volume and image visualization. We implemented missing software tools for evaluation of PET image data. For dedicated analysis of PET imaging data, a tool for calculation of the SUV in each voxel was developed. The plugin requires definition of the time interval between tracer injection and measurement, the amount of injected activity, the patient body weight and the tracer isotope. These values can be entered manually or read directly from the DICOM data, if corresponding tags are set. The SUV is calculated voxelwise for the entire image. In nuclear medicine, segmentation of regions with increased tracer uptake is often done using isocontours. These isocontours apply a threshold defined by a percentage of the maximum SUV in the lesion of interest. For example, an isocontour of 70% includes all image voxels with values ≥70% of the SUVmax (note: in the Siemens syngo system, the definition of isoncontours is inverse, so that an isocontour of 70% includes values upto SUVmax − 70% = 30%). A plugin for segmentation with isocontours was developed, which enables flexible definition of the percentage threshold.
For statistical analysis and plotting the open-source R software package was utilized (version 3.3.2, http://www.R-project.org). Kruskal-Wallis as well as two sided, unpaired Wilcoxon tests were performed including multiple testing corrections, Bonferroni-Holms/false discovery rate (FDR). Linear or monotonic relationship between two variables was investigated with Pearson- and Spearman correlation, respectively. Mantel-Cox log-rank test was used to compare differences in Kaplan-Meier survival curves (KM). Cox proportional Hazards model was used for uni/multivariate analyses (survival package, version 2.40-1, https://CRAN.R-project.org/package=survival). The significance level was set to \(\,\alpha =0.05\), two-sided tests were applied and 95% confidence intervals are reported. Sensitivity analyses together with post-hoc power/sample size calculations and bootstrapping approaches are presented where appropriate.
Segmentation
18F-FET PET images, treatment planning MRI images (T1 CE and T2 FLAIR), radiotherapy structure sets (GTV and CTV, illustrated in Fig. 1a) and follow-up MRI images (T1 CE) of each patient were exported from the clinical picture archiving system as DICOM data. Corresponding PET and MRI images were co-registered with MITK, using a multimodal rigid registration algorithm of the MatchPoint framework25, as shown in Fig. 1b. GTV and CTV from radiotherapy structure sets were mapped onto the co-registered images, as shown in Fig. 1a,c. The follow-up tumor volume GTVFU, based on the T1 CE follow-up MRI and the T2 FLAIR hyperintense volume CTVFLAIR were contoured by radiation oncologists blinded to all other imaging sequences. The progressive tumor volume was defined as P = GTV\GTVFU. On basis of the 18F-FET PET images, four different isocontour thresholds were segmented as shown in Fig. 1c: 40%, 50%, 60% and 70%, referred to as I40, I50, I60 and I70. Hereinafter, the term ‘small isocontour’ refers to higher threshold values (i.e. 70%), as higher thresholds yield smaller volumes.
Amino acid PET with 18F-FET in radiotherapy treatment planning of recurrent high grade glioma. Current standard definition of radiotherapy gross tumor volume (GTV, red) and clinical target volume (CTV, purple) are based on T1 weighted contrast-enhanced (T1 CE) MRI (a). Amino-acid PET using 18F-FET is postulated to improve target delineation by assessment of tumor metabolism (b). However, defining an appropriate cut-off for PET-active tumor region is challenging, see e.g. different PET based tumor volumes based on selected thresholds (%) from the maximum intensity (isocontours Ix, c). Comparative analysis of PET vs. MRI volumes (GTV, red) may result in substantial mismatched (d) or a relatively good overlap (e). Four different contouring techniques, using percentage threshold of the maximum standardized tracer uptake value (SUVmax), i.e. 40% (white), 50% (yellow), 60% (green) and 70% (blue) isocontours were used for segmentation of 18F-FET active volumes (c). These volumes were then compared to T1 CE MRI based radiotherapy target volumes (GTV and CTV). Boxplots show the distribution of the individual volumes in grade III and IV recurrent glioma, respectively (f). Isocontours of 60% and 70% yielded significantly smaller volumes compared to GTV in grade IV glioma. Boxplots in (g) show the fraction of each isocontour volume that is included in either the GTV or CTV. Up to 50% of the PET derived isocontour volumes are not included in the GTV in grade IV glioma, whereas more than 75% of all isocontour volumes are included in the CTV volumes.
Definition and quantitative comparison of tumor volumes
Volumes of GTV, CTV, CTVFLAIR and the four different isocontours were measured using the MITK statistics plugin. The intersection between PET contours Ix and either GTV or CTV was calculated in order to investigate the coverage of 18F-FET active regions by these volumes:
Both volume fractions were normalized to Ix, giving the percentage of coverage by either GTV or CTV.
PET images were converted to SUV images using the aforementioned SUV calculation plugin. SUVmax was determined within the GTV. Mean background uptake (SUVbg) was derived by contouring a region of similar 2D size in a part of the brain contralateral to the tumor, as previously performed13,26 (shown exemplary in Fig. 2a). In patients with a tumor in one of the hemispheres, the background region was drawn at the centrum semiovale in the non-affected hemisphere. For midline tumors, the unaffected posterior or anterior half of the brain was used to draw this region. The standardized uptake ratio (SUR) was calculated by normalizing SUVmax to the background uptake:
The volume fraction A of the isocontour Ix, which is not contained in GTV, was calculated as
Normalizing A to the GTV yields the percentage of GTV-increase by the PET active volume Ix (\(A/{\rm{GTV}}\cdot 100 \% \)), which influences the toxicity of the treatment.
Prognostic relevance of 18F-FET PET based standardized uptake ratio (SUR). SUR is calculated by normalizing SUVmax in the tumor lesion to the average background SUV (SUVbg) within a region of similar size to GTV in the contralateral part of the brain, as shown (a). SUR was slightly but not significantly higher in grade IV glioma compared to grade III glioma (b). In grade IV tumors, the median value of SUR = 2.92 clearly separated patients into two prognostic subgroups as shown in KM-plot (c). This did not apply to grade III tumors (see supplements). For PET contouring, large interindividual heterogeneity of 18F-FET PET uptake was found limiting the use of a fixed threshold for all patients as illustrated in two patients (d,e). However, based on SUR, thresholds for the reasonable applicability of isocontours could be drawn as SUR > 2.73 for an isocontour of 40%, SUR > 2.55 for an isocontour of 50% and SUR > 1.62 for an isocontour of 60%. This was not possible using SUVmax.
For quantification of the overlap between isocontour Ix and GTV, the conformity index (CI) was defined as the intersection of both contours, normalized to their union:
For each patient, the best matching isocontour was defined as the isocontour yielding the largest conformity index CImax. Corresponding threshold values of the SUR were calculated (\({I}_{x}\cdot {\rm{SUR}}\)), in order to relate the best matching isocontour to segmentations that are based on uptake-to-background thresholds.
Overlap between additional 18F-FET active volume A and progression of the tumor P was investigated by calculating the intersection J = A \(\cap \) P. J was normalized to either A or P, giving the corresponding percentage value of coverage.
J/A labels the specificity of 18F-FET for detection of progression patterns, whereas the percentage of progression volume which is covered by the PET volume (J/P) is the sensitivity of 18F-FET for detection of tumor progression. Note: In conventional nomenclature, J/A is denoted as positive predictive value, as it is the ratio of true positives over all positives. Specificity in the classical meaning is the ratio between true negatives and the sum of false positives and true negatives. However, the amount of true negatives in this case is unknown, as it would be the volume of the entire brain which is not 18F-FET enhancing.
Finally, the intersection between PET contour Ix and CTVFLAIR was calculated, in order to investigate the coverage of 18F-FET active regions by T2 FLAIR hyperintense volumes:
The fraction of Ix that is not included in CTVFLAIR \(({I}_{x}\backslash CT{V}^{FLAIR})\) was normalized to Ix, giving the percentage of isocontour volume that is not covered by the T2 FLAIR hyperintense volume.
Results
Median overall survival after this second course of radiotherapy was 27.5 months [4 to 60 months] in patients with grade III glioma and 9 months [2 to 28 months] in patients with grade IV glioma. 19 patients showed progression of the tumor after therapy, 6 in grade III glioma and 13 in grade IV glioma, leading to a median progression free survival of 7.5 months in grade III patients and 2 months in grade IV patients. Median follow up was 29.3 months.
The radiotherapy structure set (GTV, CTV) was fused with the MRI T1 CE and T2 FLAIR as well as with the gradually increasing thresholds for 18F-FET PET positive isocontours. Representative images of different isocontour volumes compared to the respective treatment planning GTV and CTV for grade III as well as IV glioma are presented in Fig. 1. The fraction of coverage of the respective isocontours by either GTV or CTV as percentage value is shown in Fig. 1d. The median GTV volume was larger in grade IV vs. grade III tumors (39.09 ml vs 10.78 ml, \(p\,=\,0.0129\)). The volumes of isocontours decreased with increasing threshold values reflecting the higher stringency for defining tumor positive regions by 18F-FET PET. I60 and I70 volumes were significantly smaller than GTV in grade IV tumors (\(p\,=\,0.013\) and \(p\,=\,0.00067\), respectively). Considering 10% increase in GTV by inclusion of the PET active volume a substantial change (\({\rm{A}}/\text{GTV}\,\cdot 100 > 10 \% \)), I40 added substantial volumes to the GTV in 2 cases (50%) for grade III glioma and in 7 cases (78%) for grade IV glioma. I50 added substantial volumes to the GTV in 4 (57%) (grade III glioma) and 5 (46%) (grade IV glioma) cases. I60 added substantial volumes in 4 (50%) (grade III) and 6 (46%) cases (grade IV). I70 added substantial volumes in 55% (6 cases, grade III) and 14% (2 cases, grade IV) of the patients.
18F-FET Uptake Ratio
Individualized tumor 18F-FET PET uptake ratios were measured by comparing the SUVmax with background (contralateral side, SUVbg, Fig. 2a). One patient presented with extremely low tracer uptake of SUR = 1.15 (SUVmax = 1.1) and was thus excluded from further analysis. The boxplot in Fig. 2b shows overall SUR for patients with grade III and grade IV glioma. SUR values in grade III glioma took a wide range of values (1 up to 5). In grade IV tumors, the range between 25th and 75th quantile was smaller ([1.61; 3.18] for grade III vs. [2.64; 3.55] for grade IV). There was a trend for higher SUR in grade IV vs. III glioma but it does not reach statistical significance (p = 0.262). In grade III tumors, SUR did not show any significant correlation with overall survival (Supplemental Fig. 1). In grade IV tumors, the median SUR clearly separated patients into a good prognosis (SUR > 2.92) with significant increase (~50%) of median survival (13 months) vs. poor (SUR < 2.92) prognosis group with a median survival of only 6 months (p = 0.00016, Fig. 2c). Accordingly, univariate analysis for correlation between SUR and survival yielded a hazard ratio of HR = 4.1 with 95% confidence intervals of [1.4–11.6] in grade IV glioma (p = 0.007). Significance of the results remained when including age and gender into a multivariate analysis; SUR: HR = 3.99, [1.4; 11.6], p = 0.013; Gender: HR = 0.67, [0.15; 3.1], p = 0.8; Age: HR = 1.02, [0.96–1.1], p = 0.49. Sensitivity analyses were conducted and parameter distributions obtained by boostrapping to allow further assessment of the results and to assure their validity (see Supplements).
Our data indicated that not every contouring technique could be applied in every patient. In patients with low tracer uptake, isocontours with lower thresholds, like I40 or I50, tend to yield unreasonably large volumes as they include scattered small segmentations from noisy background. Representative images of two different patients are illustrated in Fig. 2d,e. Due to low uptake, I40 failed in 12 patients (48%). I50 was not applicable in 7 patients (28%) and I60 in 4 patients (16%).
Careful examination of the individual contours in every patient and corresponding SUR of the lesion lead to thresholds for applicability of different isocontours: for I40: SUR ≥ 2.73, for I50: SUR ≥ 2.55, for I60: SUR ≥ 1.63. The thresholds were deduced as the lowest SUR value in the patient where application of the respective isocontour still yielded a reasonable segmentation.
Conformity between MRI based GTV and PET isocontours
Our approach for quantification of overlap between the GTV and different PET isocontours (Ix) and definition of the conformity index (CI) is schematically shown in Fig. 3a. Results of the conformity analysis are summarized in Fig. 3. The distribution of CI for the different isocontour thresholds are shown in 3b. Conformity decreases with higher isocontour thresholds, especially in grade IV tumors. Higher thresholds yield smaller volumes, and subsequently, higher isocontour thresholds result in smaller intersections with the GTV.
Quantification of overlap between different isocontour thresholds and MRI based GTV - the conformity index. The conformity index of each isocontour volume in a patient was calculated as intersection between isocontour and GTV normalized to their union, as schematically shown in (a). Boxplots in (b) show the distribution of conformity indices for every isocontour threshold. Higher thresholds (60%, 70%) yielded lower conformity, especially in grade IV glioma. The best matching isocontour was defined at the threshold yielding the highest conformity index with GTV. The corresponding highest conformity index is denoted as CImax. CImax showed a non-significant trend towards correlation with SUV and SUR (c), especially in grade IV tumors, indicating that higher uptake tends to yield better conformity. Applying the best matching isocontour percentage threshold to the SUR of a patient yielded a corresponding SUR cutoff that the best matching isocontour would correspond to. For all given isocontour thresholds these cutoffs were distributed over a broad range of SUR values (d), and did not cluster into individual groups.
The maximum conformity index CImax, derived from the best matching isocontour, over SUVmax and SUR of the patient were calculated (Fig. 3c). In both grade III and IV tumors, a slight, but non-significant correlation between SUR or SUVmax of the lesion and maximum conformity index CImax, derived from the best matching isocontour, could be observed (Fig. 3c). The effect was strongest between SUR and CImax in grade IV tumors, with a Pearson correlation of R = 0.36 and a Spearman correlation of R = 0.56 \((p\,=\,0.21)\). For all other correlation coefficients, refer to Supplementary Table 2.
Applying the percentage value of the best matching isocontour to the patients SUR value yields the corresponding SUR cutoff (or SUR threshold), a value often used for 18F-FET PET delineation in the literature. CImax in dependence of the cutoff values of each patient are presented (Fig. 3d). The corresponding isocontours are labeled by different shapes. It can be observed that SUR cutoff values for individual isocontours do not cluster into separate groups, but are instead spread out over a wider range of SUR and CImax values. Hence, our data illustrate the limitation of defining a fixed SUR threshold for 18F-FET PET contouring.
Does PET-MRI discordance indicate regions at risk for tumor progression?
The identified mismatches between isocontours and GTV could indicate tumor regions at risk for progression. Therefore, the intersection (J) of the additional PET volume (A) with the tumor volume at progression (P) was evaluated. A denotes added PET volume outside GTV, i.e. PET-positive while MRI negative region at risk, at a given isocontour. J volume depicts added PET volume that corresponded with tumor growth at follow up. Together, specificity (J normalized to A) and sensitivity (J normalized to P) was identified for different PET isocontours (Ix, Fig. 4).
Detection of potential tumor progression by 18F-FET PET. The progressive tumor volume P was assessed by contouring the progressed tumor GTVFU on the follow-up T1 CE MRI and calculating the difference to the original GTV: P = GTV\GTVFU. Of the 16 patients investigated, only n = 3 patients showed an in-field progression pattern. Therefore, the predominant failure pattern was “marginal” with 83% of patients (n = 12 patients) developing recurrences at the edges of the carbon ion field (CTV) underscoring the need for better delineation of the target volume. To evaluate, whether the PET isocontour volume A = Ix\GTV outside of GTV could indicate parts of the progressed tumor volume, the intersection J between A and P was calculated with J = A\P, as schematically shown in (a). The sensitivity (b), percentage of progressive tumor volume that is covered by the additional PET active volume (J/P), and specificity (c), percentage of 18F-FET PET active volume that includes areas of tumor progression (J/A), of the additional 18F-FET active volume to detect regions at risk for tumor progress are shown. In grade III glioma, sensitivity decreases with increasing isocontour thresholds, whereas specificity increases with increasing isocontour thresholds. In grade IV glioma sensitivity decreased with increasing isocontour thresholds. Images in (d) show three axial slices in an example patient (grade IV) with low sensitivity and specificity, i.e. little overlap between 18F-FET PET (yellow line) and progress (blue line).
From 19 patients who showed progression of the tumor after carbon ion therapy, complete follow-up imaging data was only available for 17, 5 with grade III glioma (from which one was excluded due to low tracer uptake, see above) and 12 with grade IV glioma. Interestingly, using the definition by Chan et al.27, of the 16 patients with progression investigated, only 3 showed an in-field progression (80–95% of progressive tumor within CTV) and 12 showed a marginal progression pattern (20–80% of progressive tumor within CTV). One case showed a distant progression pattenr (<20% of progressive tumor within CTV).
For grade III glioma, the individual values are shown as only 4 patients were found in this subgroup (Fig. 4b), and e.g. I40 was applicable in only one of them. Plots in Fig. 4b show a decreasing trend of sensitivity with higher isocontour thresholds. Whereas in grade III tumors, larger PET contours (I40 and I50) cover about half of the progressive tumor volume (J/P ≈ 50%), I40 covered only about 15% and I70 covered about 2% of the progressive tumor volume in grade IV tumors.
The percentage of additional PET volume that overlaps with the progressive tumor volume (J/A, specificity) appears to increase with higher isocontour thresholds in grade III glioma. This trend cannot be found in grade IV glioma, where I60 and I70 cover almost the entire spectrum, from 0% up to 90%. In both grade III and grade IV glioma, the range of values for J/A broadens with higher isocontour thresholds. Overall, coverage of the progressive tumor volumes is non-specific, and large parts of the additional PET active volumes seem to not correlate with tissue at risk for tumor progression.
In summary, these results indicate that only a small fraction of the progressive tumor volume is overlapping with the 18F-FET PET active tissue. Especially in grade IV tumors, 18F-FET demonstrates low sensitivity and low specificity to identify tumor tissue at risk for progression.
Overlap of PET positive volume with T2 FLAIR based CTV
Novel consensus guidelines on radiotherapy target delineation suggest inclusion of T2 FLAIR hyperintense regions into CTV7. Our results indicate significant volume differences between current T1 CE based CTV and T2 FLAIR hyperintense volume CTVFLAIR in grade IV tumors (p = 0.009, Fig. 5). In contrast, no significant difference between the two different CTV approaches was found in grade III glioma (p = 0.2). Furthermore, CTVFLAIR was significantly larger in grade IV compared to grade III tumors (p = 0.026). Next, we studied the overlap between the 18F-FET regions and T2 FLAIR hyperintense volumes. 15 of the patients with tumor progression received T2 FLAIR scans for the treatment planning MRI. The percentage volume of the PET isocontours outside of CTVFLAIR was quantified
Coverage of 18F-FET PET isocontour volumes by T2 FLAIR hyperintense regions. Novel guidelines suggest inclusion of regions that are hyperintense on T2 FLAIR MRI (orange) into CTVFLAIR (a). In grade IV glioma, this significantly increases the volume of CTV (b). The fraction of the 18F-FET PET based isocontour volumes that lies outside of the T2 FLAIR hyperintense volume, was calculated (c). With two exceptions for isocontours of 70% in grade III tumors and three exceptions for isocontours of either 60% or 70% in grade IV tumors, more than 80% of the isocontours were covered by the T2 FLAIR hyperintense volume (c). Representative patient with grade IV glioma where over 90% of the 18F-FET PET active area lies within CTVFLAIR (d). Exemplary cases of two exceptional patients circled in red in the boxplots (c) with large fractions of the isocontour volumes (70% and 60%) laying outside the T2 FLAIR hyperintense volume are shown.
With a few exceptions, most of the PET volumes (~90%) are included in the T2 FLAIR hyperintense volumes, in both grade III and IV glioma (Fig. 5c). Two exemplary cases (one of each WHO grade) presenting with large mismatches between PET based contour and FLAIR volume are shown in Fig. 5d,e. The corresponding values are labeled by red circles in 5c.
Our results indicate that 18F-FET PET is well covered by CTVFLAIR with limited added value for tumor delineation, especially when considering the low specificity of PET positive tumor volume to predict regions at risk for tumor progression.
Discussion
Local therapy failure leading to tumor recurrence in proximity of the irradiated region is the major obstacle in curative treatment of HGG28. Current standard target volume definition in radiotherapy treatment planning of HGG is based predominantly on T1 weighted contrast enhanced MRI. 18F-FET PET may be a promising candidate to assist in radiotherapy tumor segmentation. Defining a meaningful 18F-FET PET activity cutoff to accurately identify vital tumor region versus surrounding normal tissue constitutes a major challenge. We utilized gradual intensity thresholds leading to different isocontours and systematically correlated the discordance between PET vs. MRI based tumor volumes with tumor growth pattern after carbon ion irradiation. Contour intersections were analyzed in terms of conformity, sensitivity and specificity of PET positive volumes to identify regions at risk for tumor progression. It was further studied whether a threshold for best matching SUV, SUR and isocontour could be defined.
We found no significant difference in median 18F-FET PET SUV/SUR between patients with grade III and grade IV glioma. This observation is in line with previously reported data (14, 15). However, reports also exist suggesting a correlation between 18F-FET SUR and glioma grade (16). One plausible explanation for the observed discrepancies was linked to possible differences in SUR outcome depending on the time point of PET scan after tracer injection (17). Therefore, dynamic 18F-FET PET scans might solve existing controversies.
We found that the median 18F-FET SUR of 2.92 robustly divided recurrent grade IV glioma into prognostic subgroups (HR: 4.1, p = 0.013). To our knowledge, this is the first evidence on the prognostic value of 18F-FET SUR for outcome of carbon ion irradiation. Interestingly, ~10% decrease in 18F-FET PET SUR after conventional radiochemotherapy was found to distinguish early responders in primary treatment of HGG18. Together with our observation, additional longitudinal 18F-FET SUR investigation in grade IV may be promising for discovery of novel prognosticators of radiotherapy response in this disease. Based on differences observed between grade III and grade IV glioma in our study, these tumor entities may be investigated separately in future 18F-FET PET trials.
We found no consensus SUV/SUR cut-off to reliably select 18F-FET positive isocontours to delineate tumor volume. Less stringent isocontours tend to yield better conformity with the MRI contrast-enhancing tumor for grade III glioma. In grade IV tumors, I40 represented the best matching isocontour in most cases. The increase in treatment volume as indicated by 18F-FET uptake varies greatly between different isocontour thresholds. Consequently, different segmentation techniques may greatly influence the size of target volume definition and augment toxicity of the irradiation.
Despite existing recommendations for 18F-FET PET delineation strategies, their impact on radiotherapy target volumes and outcome as well as congruence with other standard imaging modalities is still controversially debated20,29,30. Defining a fixed threshold for SUV was not feasible as 18F-FET uptake is relatively low (vs. e.g. FDG uptake) and varies greatly between patients12. For isocontours, different threshold values (40–90%) are in practice, but the optimal threshold value to be used is still unclear14. This also applies to recommended SUR based thresholds11,19,22. Our results indicate that fixed SUR thresholds are not suitable for delineation of 18F-FET PET in radiotherapy target definition generating variable conformity with the MRI based GTV. However, mismatches between MRI and 18F-FET PET can also result from tumor growth in the time interval between acquisition of the two modalities. Hence, multimodal imaging with combined PET-MRI scanners might help in further characterizing and quantifying mismatches and thus clarify the additional value of 18F-FET PET.
Previous studies incorporating 18F-FET PET active regions into the target volume definition reported mismatches between MRI based and amino acid PET derived contours10,12,22,29,30. It was therefore postulated that the PET positive regions not covered by current MRI based methods may indicate regions at risk for local tumor failure due to underdosing of radiotherapy. Our data does not support this hypothesis in recurrent HGG. Tumor growth pattern analysis revealed that 18F-FET PET identifies regions at risk for tumor progression after carbon ion therapy with low sensitivity and low specificity. Therefore, inclusion of 18F-FET PET active regions may result in coverage of a low fraction of regions at risk for tumor progression at the cost of substantially larger irradiated volumes. As novel RT target delineation guidelines recommend the inclusion of T2 FLAIR hyperintense regions into the treatment planning CTV7, we investigated the impact of such a contouring strategy on the coverage of 18F-FET PET active volumes. Interestingly, less than 10% of the PET active volume was found to be outside of the T2 FLAIR volume. Consequently, introduction of CTVFLAIR in radiotherapy planning would lead to substantial coverage of 18F-FET active regions.
We investigated patients with recurrent glioma because no surgical resection of the tumor was performed prior to the second course of irradiation, and thus, correlation between pre- and post-therapy MRI images was not biased by spatial deformations. The extent to which our findings could be translated to treatment of primary glioma remains to be elucidated. While initial conclusions could be drawn from the 26 investigated patients, prospective randomized trials such as NOA10/ARO2013-131 could provide definitive proof and validate the impact of our findings. The prevailing failure pattern (>90%) of conventional radiotherapy are “central or in-field” progressions, i.e., >80% of the recurrent tumor volume is localized in the high-dose radiation field (CTV28). In contrast, we found that only ~17% of failure were in the carbon ion field and the majority (~83%) of tumors showed a “marginal” progression pattern at the borders of carbon ion CTV. Therefore, identification of the tumor infiltration area will be of utmost importance for defining the target volume and the success of high precision irradiation with carbon ions. Moreover, different biological models underlying carbon ion dose distributions32 were not considered in the present study, which might impact tumor progression pattern analysis. Further studies including irradiation dose distribution should be conducted, which will become available within the MITK framework for implementations of biological particle therapy dose models. Our data clearly suggest the use of 18F-FET PET as prognosticator for carbon ion treatment of grade IV glioma. Combination of PET with other novel molecular based prognosticators33,34 may assist in stratifying patients benefiting most from carbon ion irradiation.
Conclusion
The missing target hypothesis postulates that current MRI does not allow accurate detection of infiltrative growth pattern of high-grade glioma (HGG) limiting the efficacy of radiotherapy. Tumor metabolic switch leads to selective uptake of amino-acids such as 18F-FET and has fueled the hope to improve radiotherapy via a better delineation of HGG. We report high interindividual heterogeneity of tumor 18F-FET uptake limiting selection of a common reliable and robust threshold. Moreover, PET-positive volumes outside the current MRI-based tumor definition showed low sensitivity and specificity for identifying regions at risk for tumor progression. The prevailing patterns of radiotherapy failure are central or in-field recurrences. In our study, the predominant progression pattern was at the margins of the carbon ion irradiation field underscoring the urgent need for precise target definition for the success of this novel therapy modality. Patients with grade IV glioma showed significantly longer overall survival in cases of lower tumor 18F-FET uptake, demonstrating the prognostic value of amino acid PET.
References
Nieder, C., Grosu, A. L., Mehta, M. P., Andratschke, N. & Molls, M. Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev. Neurother. 4, 691–703 (2004).
Gaspar, L. E. et al. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. 24, 55–57 (1992).
Minniti, G. et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother. Oncol. 97, 377–381 (2010).
Niyazi, M. et al. Therapeutic options for recurrent malignant glioma. Radiother. Oncol. 98, 1–14 (2011).
Stupp, R. et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Niyazi, M. et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother. Oncol. 118, 35–42 (2016).
Grosu, A.-L. & Weber, W. A. PET for radiation treatment planning of brain tumours. Radiother. Oncol. 96, 325–327 (2010).
Weber, D. C. et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat. Oncol. 3, 44 (2008).
Grosu, A. L. et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. 63, 511–519 (2005).
Moller, S. et al. Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. Radiother. Oncol. 121, 132–137 (2016).
Rieken, S. et al. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother. Oncol. 109, 487–492 (2013).
Niyazi, M. et al. Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. J. Neurooncol. 110, 389–395 (2012).
Pöpperl, G. et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur. J. Nucl. Med. Mol. Imaging 31, 1464–1470 (2004).
Pöpperl, G. et al. Analysis of 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Kinetics Superior to Standard Methods? J. Nucl. Med. 47, 393–403 (2006).
Pöpperl, G. et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur. J. Nucl. Med. Mol. Imaging 34, 1933–1942 (2007).
Weckesser, M. et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur. J. Nucl. Med. Mol. Imaging 32, 422–429 (2005).
Piroth, M. D. et al. Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. Int. J. Radiat. Oncol. 80, 176–184 (2011).
Pauleit, D. et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128, 678–687 (2005).
Zaidi, H. & Naqa, I. E. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur. J. Nucl. Med. Mol. Imaging 37, 2165–2187 (2010).
Langen, K.-J. et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 33, 287–294 (2006).
Niyazi, M. et al. FET–PET for malignant glioma treatment planning. Radiother. Oncol. (2011).
Scholz, M., Kellerer, A. M., Kraft-Weyrather, W. & Kraft, G. Computation of cell survival in heavy ion beams for therapy. The model and its approximation. Radiat. Environ. Biophys. 36, 59–66 (1997).
Nolden, M. et al. The Medical Imaging Interaction Toolkit: challenges and advances. Int. J. Comput. Assist. Radiol. Surg. 8, 607–620 (2013).
Floca, R. MatchPoint: On Bridging the Innovation Gap between Algorithmic Research and Clinical Use in Image Registration. in World Congress on Medical Physics and Biomedical Engineering, September 7–12, 2009, Munich, Germany(eds. Dössel, O. & Schlegel, W. C.) 1105–1108 (Springer Berlin Heidelberg, 2009) https://doi.org/10.1007/978-3-642-03882-2_294
Unterrainer, M. et al. Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res. 7 (2017).
Chan, J. L. et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 20, 1635–1642 (2002).
Debus, J. & Abdollahi, A. For the next trick: new discoveries in radiobiology applied to glioblastoma. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet. e95–99, https://doi.org/10.14694/EdBook_AM.2014.34.e95 (2014).
Gempt, J. et al. Volumetric Analysis of F-18-FET-PET Imaging for Brain Metastases. World Neurosurg. 84, 1790–1797 (2015).
Vees, H. et al. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur. J. Nucl. Med. Mol. Imaging 36, 182–193 (2008).
Oehlke, O. et al. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 16, 769 (2016).
Mairani, A. et al. Modelling of cell killing due to sparsely ionizing radiation in normoxic and hypoxic conditions and an extension to high LET radiation. Int. J. Radiat. Biol. 89, 782–793 (2013).
Mock, A. et al. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int. J. Cancer 139, 424–432 (2016).
Geisenberger, C. et al. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathol. (Berl.) 130, 419–434 (2015).
Acknowledgements
We thank Klaus Maier-Hein, Marco Nolden and their team for development and implementation of radiotherapy structure sets MITK plug-in and excellent software support. This work was supported by the National Center for Tumor diseases (NCT 3.0-2015.22 BioDose, to AA/JD), German Research Foundation (DFG-KFO-214, to AA/JD), Federal Ministry of Education and Research Germany (BMBF 01IB13001B, to RF) and Deutsche Krebshilfe (Max-Eder 108876, to AA). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
C.D., M.K., J.D. and A.A. designed the study and conceived the analysis. S.A., S.H., M.B., W.W., S.R. and U.H. were responsible for data acquisition. R.F. and N.B. supplied the necessary software and RadPlanBio support. C.D., M.W. and M.K. analyzed the data. C.D., M.K. and A.A. wrote the manuscript. All authors critically revised the manuscript.
Corresponding authors
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Debus, C., Waltenberger, M., Floca, R. et al. Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. Sci Rep 8, 7201 (2018). https://doi.org/10.1038/s41598-018-25350-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-018-25350-7
- Springer Nature Limited
This article is cited by
-
A multi-label CNN model for the automatic detection and segmentation of gliomas using [18F]FET PET imaging
European Journal of Nuclear Medicine and Molecular Imaging (2023)
-
Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates
European Radiology (2021)
-
18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection
Journal of Neuro-Oncology (2021)
-
Quantitative biparametric analysis of hybrid 18F-FET PET/MR-neuroimaging for differentiation between treatment response and recurrent glioma
Scientific Reports (2019)
-
FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma
European Journal of Nuclear Medicine and Molecular Imaging (2019)